Credit Suisse Group AG Initiates Coverage on MediciNova, Inc. (MNOV)

Credit Suisse Group AG initiated coverage on shares of MediciNova, Inc. (NASDAQ:MNOV) in a research note released on Tuesday, April 18th. The brokerage issued an outperform rating on the biopharmaceutical company’s stock.

Shares of MediciNova (NASDAQ:MNOV) traded down 1.43% during midday trading on Tuesday, hitting $5.52. 21,488 shares of the company traded hands. MediciNova has a 52 week low of $4.85 and a 52 week high of $8.00. The stock’s market capitalization is $190.66 million. The company has a 50-day moving average price of $5.62 and a 200-day moving average price of $6.24.

WARNING: This story was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at

In other news, Director Yutaka Kobayashi purchased 24,000 shares of the stock in a transaction that occurred on Friday, May 12th. The shares were purchased at an average cost of $5.62 per share, with a total value of $134,880.00. Following the completion of the acquisition, the director now owns 81,800 shares of the company’s stock, valued at approximately $459,716. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 15.60% of the company’s stock.

About MediciNova

Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

5 Day Chart for NASDAQ:MNOV

Receive News & Ratings for MediciNova Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply